An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. (14th April 2009)
- Record Type:
- Journal Article
- Title:
- An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. (14th April 2009)
- Main Title:
- An NMR Study of the Bortezomib Degradation under Clinical Use Conditions
- Authors:
- Bolognese, Adele
Esposito, Anna
Manfra, Michele
Catalano, Lucio
Petruzziello, Fara
Martorelli, Maria Carmen
Pagliuca, Raffaella
Mazzarelli, Vittoria
Ottiero, Maria
Scalfaro, Melania
Rotoli, Bruno - Other Names:
- Vesole David H. Academic Editor.
- Abstract:
- Abstract : The (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl-boronic acid, bortezomib (BTZ ), which binds the 20S proteasome subunit and causes a large inhibition of its activity, is a peptidomimetic boronic drug mainly used for the treatment of multiple myeloma. CommercialBTZ, stabilized as mannitol derivative, has been investigated under the common conditions of the clinical use because it is suspected to be easily degradable in the region of its boronic moiety. CommercialBTZ samples, reconstituted according to the reported commercial instructions and stored at4 ∘ C, were analyzed by high-field nuclear magnetic resonance spectroscopy in comparison with identical samples bubbled with air and argon, respectively. All the samples remained unchanged for a week. After a month, the air filled samples showed the presence of two main degradation products (6% of starting material), the N-(1-(1-hydroxy-3-methylbutylamino)-1-oxo-3-phenylpropan-2-yl) pyrazine-2-carboxamide (BTZ1 ; 5%, determined from NMR integration) and the (S)-N-(1-(3-methylbutanamido)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (BTZ2 ; 1%, determined from NMR integration), identified on the basis of their chemical and spectroscopic properties. TheBTZ1 andBTZ2 finding suggests that, under the common condition of use and at4 ∘ C, commercial BTZ-mannitol is stable for a week, and that, in time, it undergoes slow oxidative deboronation which partially inactivates the product. LowAbstract : The (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl-boronic acid, bortezomib (BTZ ), which binds the 20S proteasome subunit and causes a large inhibition of its activity, is a peptidomimetic boronic drug mainly used for the treatment of multiple myeloma. CommercialBTZ, stabilized as mannitol derivative, has been investigated under the common conditions of the clinical use because it is suspected to be easily degradable in the region of its boronic moiety. CommercialBTZ samples, reconstituted according to the reported commercial instructions and stored at4 ∘ C, were analyzed by high-field nuclear magnetic resonance spectroscopy in comparison with identical samples bubbled with air and argon, respectively. All the samples remained unchanged for a week. After a month, the air filled samples showed the presence of two main degradation products (6% of starting material), the N-(1-(1-hydroxy-3-methylbutylamino)-1-oxo-3-phenylpropan-2-yl) pyrazine-2-carboxamide (BTZ1 ; 5%, determined from NMR integration) and the (S)-N-(1-(3-methylbutanamido)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (BTZ2 ; 1%, determined from NMR integration), identified on the basis of their chemical and spectroscopic properties. TheBTZ1 andBTZ2 finding suggests that, under the common condition of use and at4 ∘ C, commercial BTZ-mannitol is stable for a week, and that, in time, it undergoes slow oxidative deboronation which partially inactivates the product. Low temperature and scarce contact with air decrease the degradation process. … (more)
- Is Part Of:
- Advances in hematology. Volume 2009(2009)
- Journal:
- Advances in hematology
- Issue:
- Volume 2009(2009)
- Issue Display:
- Volume 2009, Issue 2009 (2009)
- Year:
- 2009
- Volume:
- 2009
- Issue:
- 2009
- Issue Sort Value:
- 2009-2009-2009-0000
- Page Start:
- Page End:
- Publication Date:
- 2009-04-14
- Subjects:
- Hematology -- Periodicals
Hematologic Diseases
Hematology
Hematology
Periodicals
Periodicals
616.15 - Journal URLs:
- http://www.hindawi.com/journals/ah/contents.html ↗
http://www.ncbi.nlm.nih.gov/pmc/journals/993/ ↗ - DOI:
- 10.1155/2009/704928 ↗
- Languages:
- English
- ISSNs:
- 1687-9104
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD Digital store
- Ingest File:
- 10291.xml